# Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy

> **NCT04394247** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 242 (actual)

## Conditions studied

- Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04394247
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-30
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 242 (ACTUAL)
- **Last updated:** 2023-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04394247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04394247, "Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04394247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*